Phenotypes Associated with This Genotype

Genotype
MGI:5575661

• Allelic Composition: Asxl1^tm1.1Iaai/Asxl1^tm1.1Iaai; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S/SvEv * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

abnormal myelopoiesis ( J:208092 )

• 6 month old mice show dysplasia of circulating myeloid cells following pI:pC treatment

extramedullary hematopoiesis ( J:208092 )

• mice treated with polyinosinicpolycytidylic acid (pI:pC) show infiltration of liver with hematopoietic cells, indicating extramedullary hematopoiesis

increased erythroid progenitor cell number ( J:208092 )

• 1.4- to 2-fold increase in CD71+/Ter119- erythoroid precursor cells in the bone marrow and spleen following pI:pC treatment, indicating impaired erythroid differentiation

decreased hemoglobin content ( J:208092 )

• hemoglobin is reduced at between 6 and 12 months of age after pI:pC treatment, but not in younger mice

increased nucleated erythrocyte cell number ( J:208092 )

• following pI:pC treatment, mice show frequent circulating nucleated red cells at 6 months of age

decreased leukocyte cell number ( J:208092 )

• following pI:pC treatment, mice develop progressive leukopenia that is most apparent at 6-12 months of age

• leukopenia is predominately as a result of decreased B220+ mature B cells, CD11b+Gr1+ neutrophils, and CD11b+Gr1- monocytes

decreased neutrophil cell number ( J:208092 )

• decrease in CD11b+Gr1+ neutrophils following pI:pC treatment

decreased mature B cell number ( J:208092 )

• mice show a decrease in B220+ mature B cells following pI:pC treatment

decreased monocyte cell number ( J:208092 )

• decrease in CD11b+Gr1- monocytes following pI:pC treatment

immune system

abnormal myelopoiesis ( J:208092 )

• 6 month old mice show dysplasia of circulating myeloid cells following pI:pC treatment

decreased leukocyte cell number ( J:208092 )

• following pI:pC treatment, mice develop progressive leukopenia that is most apparent at 6-12 months of age

• leukopenia is predominately as a result of decreased B220+ mature B cells, CD11b+Gr1+ neutrophils, and CD11b+Gr1- monocytes

decreased neutrophil cell number ( J:208092 )

• decrease in CD11b+Gr1+ neutrophils following pI:pC treatment

decreased mature B cell number ( J:208092 )

• mice show a decrease in B220+ mature B cells following pI:pC treatment

decreased monocyte cell number ( J:208092 )

• decrease in CD11b+Gr1- monocytes following pI:pC treatment

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
myelodysplastic syndrome		DOID:0050908	OMIM:614286	J:208092